Context: Recent randomized controlled trials (RCTs) provide evidence for a possible beneficial impact of vitamin D supplementation on health outcomes beyond bone health, but there are few reviews of noncalcemic adverse effects from long-term supplementation. Objective: The aims of this systematic review of vitamin D supplementation in RCTs were as follows: to determine whether all adverse effects, when combined, are reported equally between treatment arms; to identify the most common noncalcemic adverse effects reported; and to ascertain whether withdrawal rates, as a marker of clinical adverse effects, differ between treatment arms. Data Sources: The MEDLINE Ovid, Embase, and Cochrane Library databases were searched systematically up to May 2016. Study Selection: Randomized controlled trials that met the following criteria were selected: administered vitamin D 2 or D 3 supplements for a minimum supplementation or follow-up period of 24 weeks, had a placebo/control group, and were conducted among adults (! 18 y). Data Extraction: Two researchers independently screened studies for eligibility, extracted data, and carried out quality assessment of selected studies. A total of 128 studies with 52 297 participants were identified. A random-effects model was used to calculate risk ratios in a meta-analysis. Results: Long-term vitamin D 2 or D 3 supplementation, compared with placebo, did not increase all adverse effects, when combined, as reported in 62 studies with 19 389 participants (relative risk [RR] ¼ 0.97; 95%CI, 0.92-1.02). Vitamin D also did not increase the risk of the most common noncalcemic adverse effects: gastrointestinal symptoms were reported in 27 studies with 9189 participants (RR ¼ 1.01; 95%CI, 0.87-1.17), and dermatological symptoms were reported in 8 studies with 1695 participants (RR ¼ 1.33; 95%CI, 0.82-2.15). Vitamin D did not increase withdrawals from 123 studies with 41 861 participants (RR ¼ 1.03; 95%CI, 0.96-1.09). However, participants given vitamin D were more likely to report withdrawals than those given placebo in studies in which calcium was given in both arms (RR ¼ 1.16; 95%CI, 1.02-1.33) when compared with participants in studies in which calcium was not given in either arm (RR ¼ 1.00; 95%CI, 0.95-1.06; P for interaction ¼ 0.009). Conclusions: Overall, these findings suggest that vitamin D, by itself, does not increase the risk of noncalcemic adverse effects.
INTRODUCTION
The association between vitamin D status and disease risk has been investigated extensively in recent years.
Meta-analyses of observational studies, particularly cohort studies, show inverse associations between vitamin D status, as measured by circulating 25-hydroxyvitamin D [25(OH)D] concentrations, and incidence of all-cause mortality, 1 cardiovascular disease, 2 diabetes, 3, 4 and cancer. 5, 6 These findings have resulted in greatly increased numbers of randomized controlled trials (RCTs) to determine if vitamin D supplementation improves health outcomes. Meta-analyses of RCTs of vitamin D supplementation have been published, with mixed findings, for disease outcomes such as hypertension, cardiovascular disease, diabetes, cancer, respiratory tract infection, pain, and all-cause mortality. [7] [8] [9] [10] [11] [12] [13] In contrast, there are little data on the safety of long-term vitamin D supplementation. Adverse events, such as hypercalcemia, hypercalciuria, gastrointestinal (GI) symptoms, and skin disorders, have been assessed in some systematic reviews and meta-analyses of vitamin D supplementation. 12, 13 Increased risk of GI symptoms in participants taking vitamin D supplements has been reported in 1 meta-analysis. 13 Other outcomes analyzed as adverse effects in these meta-analyses include skin disorders, psychiatric disorders, cancer, cardiovascular diseases, and mortality. [12] [13] [14] However, these meta-analyses have a number of limitations with regard to safety data. First, they examined adverse events as secondary outcomes to the primary outcomes of mortality, 12 fracture risk, 13 or cancer, 14 resulting in the exclusion of RCTs that did not include the primary outcome of interest. Second, they included studies that used active forms of vitamin D for supplementation, such as calcitriol. 12, 13 Third, they included studies that compared combined vitamin D and calcium supplementation with placebo, such that any effects could have been due to either supplement or the 2 combined. Fourth, the most recent meta-analysis included studies published up to January 2013, and many more studies have been published since then.
A recently published meta-analysis of calciumrelated adverse events found that vitamin D supplementation given for 24 weeks or longer increased the risk of hypercalcemia and hypercalciuria but not the risk of renal stones. 15 Yet, there has been no recent comprehensive meta-analysis of other potential adverse events associated with long-term vitamin D supplementation. Consequently, this review aims to investigate, as the primary outcome, whether RCTs that administered supplementation with either vitamin D 3 or vitamin D 2 , along with calcium supplementation in either both arms or neither arm, for 24 weeks or longer increased the risk of other specific potential adverse events or of all adverse events combined.
In addition, withdrawals were investigated as an indirect measure of adverse effects, since it was hypothesized that withdrawals would be increased among participants given vitamin D supplementation if this supplementation was causing nonspecific effects compared with placebo. Cranny et al. 16 analyzed withdrawals in a review of observational studies and RCTs on serum vitamin D status and vitamin D supplementation in relation to bone health in adults and children. However, they assessed only the adequacy of reports on withdrawals and did not conduct a metaanalysis of withdrawals from included studies.
Therefore, the aims of this systematic review are to determine whether vitamin D supplementation, compared with placebo, increases the risk of any of the following: all adverse events combined; any commonly reported specific noncalcemic adverse event, and withdrawals.
METHODS

Search strategy
The Cochrane Library, MEDLINE (Ovid and PubMed), and Embase were searched to include studies indexed up to second week of May 2016. The search strategy included the following words: vitamin D, vitamin D 2 , ergocalciferol, vitamin D 3 , cholecalciferol, AND supplement/supplementation. This search was further limited to English-language studies, studies conducted in humans, and RCTs. Publications since 1970 onward were included. Key information on PICOS criteria (Participants/Population, Intervention, Comparator groups, Outcome, Study design) is shown in Table 1 .
Inclusion criteria
This meta-analysis included RCTs that gave either vitamin D 2 or vitamin D 3 or both, for a minimum administration or follow-up period of 24 weeks, had a placebo/control group, were conducted among adults (! 18 years), and provided data for each arm of the study.
Exclusion criteria
Studies that compared vitamin D plus calcium against placebo without calcium, were conducted in pregnant or lactating women, administered D 2 or D 3 at a dosage of more than 600 IU/d to the control arm, or included participants who were younger than 18 years were excluded. For some studies with 2 Â 2 factorial design, only those 2 arms that met the inclusion criteria were included. 17 Studies that did not specify the number of participants randomized to each arm were also excluded. 18 
Data collection method
The search was conducted by 2 researchers who screened studies for eligibility and data extraction (Z.M. and R.S.). Quality assessment (risk-of-bias assessment) of studies was conducted separately by 2 researchers (Z.M. and Z.W.) at the study level. Inconsistencies were discussed and resolved. Cases of disagreement were resolved by a third researcher (R.S.).
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram shown in Figure 1 summarizes the process by which 128 of the 355 articles that met the inclusion criteria for this review were identified.
Outcomes
After reviewing the included studies, sufficient data were available on the following outcomes: all adverse events combined; GI symptoms; dermatological symptoms; and withdrawals. In addition, where data on withdrawals were available, withdrawals due to adverse events were separated from withdrawals due to withdrawn consent.
All adverse events combined
Any adverse event other than the main outcome of a study (such as cardiovascular events, pain, cancer, mortality, etc), whether it was related to the supplementation or not, was included in all adverse events, provided it was recorded by researchers or participants and was reported per person per arm.
Gastrointestinal symptoms
Any GI-related symptom, such as nausea, vomiting, upset stomach, diarrhea, constipation, and other disorders that were reported per person per study arm were included in this category.
Dermatological symptoms
Any skin-related symptom, such as rashes, itchiness, allergic reactions, and other disorders that were reported per person per study arm were included in this category.
Withdrawals
Withdrawals were defined as the number of participants who withdrew from the study for any reason, such as withdrawn consent, adverse effects, loss to follow-up, or any other complication or worsening of health status. In some studies, the study researchers excluded noncompliant participants from the final analysis. The main approach in calculating withdrawals for included studies was to include those participants who left the study either intentionally or as a result of an adverse effect and not because of a study limitation that came to the researchers' attention, although for a few studies these separate groups could not be identified. [19] [20] [21] [22] [23] [24] [25] Hence, in those studies that did not use an intentionto-treat approach, participants who were excluded from the analysis in the middle of the study for being noncompliant were not considered withdrawn. In addition, the number of deaths was deducted from the overall number of dropouts, but not from the denominator, as those who died still remained at risk of withdrawal up to their death.
For earlier studies that lacked a CONSORT (Consolidated Standards of Reporting Trials) flow diagram and thus did not provide the exact number of participants who were excluded from each arm, withdrawals were calculated as the number of participants who completed the study in each arm minus the number of participants who were randomized to each arm. Studies that did not provide the total number of participants randomized to each arm were excluded from the meta-analysis.
Data analysis
Data were analyzed with Review Manager software using a random-effects model (RevMan version 5.2). A P < 0.05 (2-tailed) was considered statistically significant in the meta-analysis. Interactions for subgroups were tested using difference between relative risks (RRs). 26 Further subgroup analyses were run to determine whether any effect associated with vitamin D supplementation was modified by the addition of calcium to both arms, by longer periods of supplementation, or by blinding of participants and researchers. Table 2 17,19-25,27-166 summarizes the characteristics of the 128 studies included in this review. The studies had a total of 52 297 participants-26 852 from the vitamin D arm and 25 445 from the placebo arm. The mean age of participants was 57.3 years (range, 18-108 years), and 67% were women. There were 110 studies that administered a vitamin D 3 supplement, 17 that Figure S1 in the Supporting Information online. In general, most of the recent studies provided details on the randomization method and blinding. All studies except 9 17, 22, 28, 33, 41, 50, 52, 127, 159 were double blind. Allocation concealment and blinding of participants and staff were described in almost 75% and 80%, respectively, of the included studies. Funnel plots did not indicate publication bias (Figures S2-S5 in the Supporting Information online).
RESULTS
A total of 62 studies (19 389 participants) reported all combined adverse events per participant in each arm of the study. The forest plot for this analysis is shown in Figure 2 . There was no increase in the risk of all adverse events with vitamin D supplementation in studies that reported this outcome (RR ¼ 0.97; 95%CI, 0.92-1.02). Further subgroup analyses for studies with calcium in Figure 1 Flow diagram of the literature search process. 45 Avenell et al. Gastrointestinal tract symptoms in one or both arms were reported in 27 studies (9189 participants), as shown in Figure 3 . Results showed that vitamin D did not increase the risk of these symptoms (RR ¼ 1.01; 95%CI, 0.87-1.17). Further subgroup analysis for studies with vitamin D only or for studies with vitamin D in combination with calcium did not show a difference (Table 3) . Nor was the effect of vitamin D different if vitamin D was given for longer than 1 year vs 1 year or less, although only 2 studies had a follow-up period of more than 1 year. 45, 164 Further subgrouping based on a baseline 25(OH)D level of < 50 nmol/L, as opposed to !50 nmol/L, did not change the results. Interaction tests for all study subgroup comparisons showed no significant difference in the effect of vitamin D supplements on risk of GI symptoms (Table 3) .
Only 8 Subgroup analyses in studies that reported the reasons for withdrawal showed no increased risk of withdrawal due to adverse effects when compared with the risk of withdrawal due to withdrawn consent (Table 3 ; P for interaction ¼ 0.12).
Participants given vitamin D were more likely to report withdrawals than those given placebo in studies in which calcium was given in both arms (RR ¼ 1.16; Figure 5 ) when compared with participants in studies in which calcium was given in neither arm (RR ¼ 1.00; (95%CI, 0.95-1.06; Figure 6 ; P for interaction ¼ 0.009). Studies that administered supplementation for more than 1 year were more likely to report withdrawals (RR ¼ (Table 3) .
DISCUSSION
This review found no significant effect of vitamin D supplementation on risk of GI symptoms, dermatological symptoms, or all adverse events combined. Neither was the risk of withdrawal affected by vitamin D supplementation given alone, although risk was increased by vitamin D combined with calcium. Overall, the findings suggest that vitamin D by itself does not increase the risk of noncalcemic adverse effects. The finding that the risk of all adverse effects combined was not increased by vitamin D (Figure 2 ) is in line with previous metaanalyses that did not find higher risks of specific adverse effects from vitamin D supplementation. 12, 14 However, the present review also adds to existing knowledge, as it includes the first meta-analyses of all adverse events combined and of withdrawals as a marker of clinical adverse effects.
The results for GI symptoms (Table 3 ) contrast with findings of previous meta-analyses which included studies that administered either active vitamin D or vitamin D with calcium compared with placebo without calcium. 12, 13 For example, Avenell et al. 167 analyzed fracture risk in postmenopausal women and found a modest increase in GI symptoms (RR ¼ 1.04; 95%CI, 1.0-1.08; P ¼ 0.043). 13 It is noteworthy that, in their subgroup analysis, vitamin D increased GI symptoms only in those studies that also gave calcium supplements (RR ¼ 1.05; 95%CI, 1.01-1.09; P ¼ 0.025), with the highest weighting contributed by the Women's Health Initiative study. 168 In their meta-analysis of mortality prevention, Bjelakovic et al. 12 reported a 36% increase (albeit nonsignificant) in the risk of GI symptoms due to supplementation with vitamin D and its analogues (RR ¼ 1.36; 95%CI, 0.87-2.13; P ¼ 0.17). The approach of the current meta-analysis, ie, to include only studies that administered vitamin D with calcium supplementation in both arms or in neither arm, might explain the difference in effect size between this study and the 2 earlier studies.
In the current meta-analysis, there was no difference in the risk of GI symptoms between studies that used calcium in both arms vs studies that used vitamin D only in the treatment arm (Table 3 , P for interaction ¼ 0.73). However, the cumulative risk of GI symptoms for calcium (10.1% and 9.8% for calcium plus vitamin D and for calcium only, respectively) was higher than that for vitamin D only and placebo (each 5.6%). This confirms the evidence that calcium intake increases GI symptoms as investigated in the RECORD study which reported that GI symptoms were more prevalent in arms with calcium intake than those without it. 45 Similarly, in the Cochrane review of fracture risk by Avenell et al. 167 studies of vitamin D with calcium had a cumulative incidence of 18.5% and 17.7% for vitamin D and placebo arms, respectively, compared to studies without calcium which had a cumulative incidence of 6.7% and 7.1% in vitamin D and placebo arms, respectively. 13 The meta-analysis of 8 studies in this review found no increase in the risk of dermatological adverse effects with vitamin D supplementation. Likewise, the latest Cochrane review of mortality prevention found no significant impact of vitamin D on skin disorders (RR ¼ 3.27; 95%CI, 0.17-62.47; P ¼ 0.43). The results of the Cochrane review are based on 3810 participants in 2 studies, 1 of which had 3139 participants and administered vitamin D in combination with calcium in the treatment arm only. Thus, the Cochrane review had limited power to detect dermatological adverse effects of vitamin D alone (without the cointervention of calcium). Given the small number of participants in the 8 studies analyzed in the current review, as well as the elevated point estimate of effect in the Cochrane review, further research is required to determine definitively whether vitamin D causes dermatological adverse effects.
The current meta-analysis of all 123 studies with 41 861 participants found no effect of vitamin D supplementation on withdrawals (P ¼ 0.43). However, the increased effect on withdrawals from adding calcium to vitamin D (Table 3) suggests that these 2 supplements may be combining in a subtle way that is not strong enough to cause specific symptoms, since an interaction with calcium was not observed for all adverse events or GI symptoms in this review, or for calcemic adverse effects in a recent meta-analysis. 15 Of 123 studies that provided information on withdrawals, only 5 reported whether withdrawal was due to hypercalcemia. 29, 55, 85, 130, 136 These studies showed that only a small proportion of withdrawals in the vitamin D arm (4 of 70) was due to hypercalcemia, indicating that hypercalcemia is not a major reason for withdrawals in people given vitamin D supplementation.
No other systematic review and meta-analysis has investigated withdrawals from studies of vitamin D supplementation. The RCT by Avenell et al. 41 assessed the difference in withdrawals between the participants of the blinded, open-label RECORD study and found that significantly more patients in the treatment group of the open-label study withdrew compared with the control group, while there was no difference in the rate of withdrawal from the blinded study arms. 41 In the current review, there were only 9 open-label studies, and when these were separated from double-blinded trials, there was no difference in the effect of vitamin D on withdrawals ( Table 3 ). The duration of supplementation also affected the withdrawal rate. However, there were 23 studies that lasted longer than 1 year, compared with 100 studies that lasted 6 to 12 months. Considering the mean period of supplementation for all studies (1.13 years), this difference might have been detected by chance. Withdrawals were not affected by the type of vitamin D supplements. Additional data from ongoing large-scale trials of vitamin D may clarify these results in the future.
The current analyses have several limitations, including the potential loss of data caused by the exclusion of studies that reported adverse events without describing in which study arm they occurred, and by the exclusion of studies that reported adverse events that could have been counted more than once because of their inclusion in more than one category of adverse effect. The inclusion of these studies, however, is unlikely to change the results, at least for GI tract symptoms and all adverse events, as the power of this metaanalysis for each outcome was high, with 27 and 62 studies included, respectively. Another limitation is that withdrawals were defined differently between studies. Finally, early RCTs did not provide enough data on withdrawals because it was not common or necessary to provide such information before 1993. 169 This meta-analysis does have a number of strengths that increase the validity of its findings. Randomized controlled trials were included regardless of the primary outcome, resulting in a larger number of RCTs and participants than in previous meta-analyses of adverse effects, which maximized the statistical power to detect adverse effects. In addition, the effect of calcium supplements was controlled to ensure that any adverse effect was due directly to vitamin D. Finally, the subgroup analyses provided an opportunity to better identify potential factors that might modify the effect of vitamin D supplements on adverse effects or withdrawals.
CONCLUSION
This review provides a comprehensive assessment of the study outcomes from RCTs of long-term vitamin D supplementation that reported any primary outcome. Supplementation with vitamin D in its natural forms (D 2 and D 3 ) did not result in more adverse events, or more withdrawals, compared with placebo treatment. Additionally, supplementation with vitamin D did not increase the risk of GI or dermatological adverse effects.
The implication for clinicians is that this review found no harm in terms of dermatological or GI symptoms if vitamin D is administered within its upper level (UL) intake of 4000 IU/d for healthy individuals. 170 However, in light of calcium-related adverse effects reported in a recent meta-analysis, vitamin D supplements should be used with caution. 15 Ongoing megastudies of vitamin D supplementation, such as ViDA, 171 VITAL, 172 and D-Health, 173 in which large numbers of participants are followed for several years, will add substantial data on outcomes and provide clarity in any future systematic review of these outcomes. Declaration of interest. The authors have no relevant interests to declare.
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